Cardiocast

AHA drills into CV risk factors in children

Publish date: February 28, 2019

 

A weight-loss drug is poised for expanded indication, the FDA says a popular gout drug raises cardiovascular risk, an AHA statement targets CV risk factors in children, and a class action suit against the American Board of Internal Medicine over MOC gets financial support from doctors.

Amazon AlexaApple Podcasts

Google Podcasts

TuneIn

Recommended Reading

‘Simple’ way to cut PAD risk, misguided ED visits for atrial fib, and more
MDedge Cardiology
SGLT2 inhibitors morph into HF drugs
MDedge Cardiology
Biologics curb coronary artery plaques in severe psoriasis
MDedge Cardiology
Consider adopting the MESA 10-year CHD risk calculator
MDedge Cardiology
Statin adherence lower in women, minorities
MDedge Cardiology
Hormone therapy in transgender individuals may up risk of CV events
MDedge Cardiology
Who is least adherent to statins, and more
MDedge Cardiology
AHA: Consider obesity as CVD risk factor in children
MDedge Cardiology
FDA accepts supplemental New Drug Application to expand lorcaserin label
MDedge Cardiology
FDA approves label extension for dapagliflozin
MDedge Cardiology